{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:55Z","timestamp":1789014535094,"version":"build-2803163510"},"reference-count":27,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rimegepant was safe and well tolerated in a multicenter, open-label, phase 2\/3 trial for acute treatment of migraine administered as 75 mg every other day (EOD) and as needed (PRN; EOD\u2009+\u2009PRN) for 12 weeks or PRN for 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post-hoc analysis of this long-term safety study in adults was conducted according to five subgroups based on current and historical triptan use: current triptan use and no historical discontinued triptans; no current triptan use and no historical discontinued triptans (triptan-na\u00efve); and history of =1, \u22651 and \u22652 discontinued triptans. Triptan failure was defined as discontinuation of any triptan, for any reason, including insufficient response and\/or tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proportion of participants with \u22651 on-treatment adverse event (AE) was 57.6\u201366.3% across triptan subgroups. Rimegepant-related AEs (17.7\u201323.2%), treatment discontinuations (1.6\u20133.8%) and the most common AE (upper respiratory tract infection, 7.7\u20139.5%) were consistent across subgroups. After long-term treatment, the proportion of participants who preferred rimegepant to their previous medication was &gt;75% in all triptan subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term acute treatment of migraine with rimegepant 75 mg up to once daily was safe and well tolerated in triptan-na\u00efve participants, current triptan users and those with single or multiple historical triptan discontinuations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>NCT03266588.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024251343309","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T11:49:47Z","timestamp":1752061787000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Rimegepant safety and patient-reported outcomes among triptan-na\u00efve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-4927","authenticated-orcid":false,"given":"Jessica","family":"Ailani","sequence":"first","affiliation":[{"name":"Medstar Georgetown University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C","family":"Pixton","sequence":"additional","affiliation":[{"name":"US Medical Affairs, Pfizer Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Fullerton","sequence":"additional","affiliation":[{"name":"US Medical Affairs, Pfizer Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_3_3_3_2","article-title":"Sumatriptan (oral route of administration) for acute migraine attacks in adults","volume":"2012","author":"Derry CJ","year":"2012","unstructured":"Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 2012: Cd008615.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01494-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12404"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00292.x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12164"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01781-z"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221141686"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00126-6"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241232944"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/25158163221075596"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00752.x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2001.01156.x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00030.x"},{"key":"e_1_3_3_19_2","volume-title":"ECDEU Assessment manual for psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W. ECDEU Assessment manual for psychopharmacology. National Institute of Mental Health, 1976."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01502-z"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00626-1"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000133207.70312.30"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/JXX.0000000000000397"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1027-7"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13588"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080107","article-title":"Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis","volume":"386","author":"Karlsson WK","year":"2024","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA, et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. Br Med J 2024; 386: e080107.","journal-title":"Br Med J"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00824-5"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251343309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024251343309","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251343309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:57Z","timestamp":1777387617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024251343309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/03331024251343309"],"URL":"https:\/\/doi.org\/10.1177\/03331024251343309","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"03331024251343309"}}